JP2016508145A - ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 - Google Patents
ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 Download PDFInfo
- Publication number
- JP2016508145A JP2016508145A JP2015551200A JP2015551200A JP2016508145A JP 2016508145 A JP2016508145 A JP 2016508145A JP 2015551200 A JP2015551200 A JP 2015551200A JP 2015551200 A JP2015551200 A JP 2015551200A JP 2016508145 A JP2016508145 A JP 2016508145A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- benzyloxy
- pyran
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- URUYUPWMQDGVOW-UHFFFAOYSA-N CC(C(C=C1)S(NCC(OC=C2OCc3ccccc3)=CC2=O)(=O)=O)C=C1Cl Chemical compound CC(C(C=C1)S(NCC(OC=C2OCc3ccccc3)=CC2=O)(=O)=O)C=C1Cl URUYUPWMQDGVOW-UHFFFAOYSA-N 0.000 description 1
- IUAUAUVHPXRJQP-UHFFFAOYSA-N CC(C)NC(C(N(C)C(CNS(c1ccccc1)(=O)=O)=CC1=O)=C1O)=O Chemical compound CC(C)NC(C(N(C)C(CNS(c1ccccc1)(=O)=O)=CC1=O)=C1O)=O IUAUAUVHPXRJQP-UHFFFAOYSA-N 0.000 description 1
- LNBLCYBIHQUCPL-UHFFFAOYSA-N CC(C)NC(C(N(C)C(CNS(c1ccccc1)(=O)=O)=CC1=O)=C1OCc1ccccc1)=O Chemical compound CC(C)NC(C(N(C)C(CNS(c1ccccc1)(=O)=O)=CC1=O)=C1OCc1ccccc1)=O LNBLCYBIHQUCPL-UHFFFAOYSA-N 0.000 description 1
- JKEUAEQMMZPLJV-UHFFFAOYSA-N CN(C(CNS(c1ccccc1)(=O)=O)=CC1=O)C(C(O)=O)=C1O Chemical compound CN(C(CNS(c1ccccc1)(=O)=O)=CC1=O)C(C(O)=O)=C1O JKEUAEQMMZPLJV-UHFFFAOYSA-N 0.000 description 1
- PPNAKZUJXGZNBS-UHFFFAOYSA-N CN(C(CNS(c1ccccc1)(=O)=O)=CC1=O)C(C(O)=O)=C1OCc1ccccc1 Chemical compound CN(C(CNS(c1ccccc1)(=O)=O)=CC1=O)C(C(O)=O)=C1OCc1ccccc1 PPNAKZUJXGZNBS-UHFFFAOYSA-N 0.000 description 1
- FZLFWCWHMUBTDR-UHFFFAOYSA-N Cc(cccc1)c1S(NCC(N(C)C(C(O)=O)=C1O)=CC1=O)(=O)=O Chemical compound Cc(cccc1)c1S(NCC(N(C)C(C(O)=O)=C1O)=CC1=O)(=O)=O FZLFWCWHMUBTDR-UHFFFAOYSA-N 0.000 description 1
- DFKWNUSFUBUGAY-UHFFFAOYSA-N Cc(cccc1)c1S(NCC(N(C)C(C(O)=O)=C1OCc2ccccc2)=CC1=O)(=O)=O Chemical compound Cc(cccc1)c1S(NCC(N(C)C(C(O)=O)=C1OCc2ccccc2)=CC1=O)(=O)=O DFKWNUSFUBUGAY-UHFFFAOYSA-N 0.000 description 1
- GFUVTBAOJSGQRO-UHFFFAOYSA-N Cc1cccc(S(NCC(N(C)C(C(O)=O)=C2O)=CC2=O)(=O)=O)c1 Chemical compound Cc1cccc(S(NCC(N(C)C(C(O)=O)=C2O)=CC2=O)(=O)=O)c1 GFUVTBAOJSGQRO-UHFFFAOYSA-N 0.000 description 1
- FIDRDTKVCQZYTB-UHFFFAOYSA-N Cc1cccc(S(NCC(N(C)C(C(O)=O)=C2OCc3ccccc3)=CC2=O)(=O)=O)c1 Chemical compound Cc1cccc(S(NCC(N(C)C(C(O)=O)=C2OCc3ccccc3)=CC2=O)(=O)=O)c1 FIDRDTKVCQZYTB-UHFFFAOYSA-N 0.000 description 1
- KTOUCTSVEYVGJW-UHFFFAOYSA-N Cc1cccc(S(NCC(OC(C(O)=O)=C2OCc3ccccc3)=CC2=O)(=O)=O)c1 Chemical compound Cc1cccc(S(NCC(OC(C(O)=O)=C2OCc3ccccc3)=CC2=O)(=O)=O)c1 KTOUCTSVEYVGJW-UHFFFAOYSA-N 0.000 description 1
- VXQJFEQLHMJJLG-UHFFFAOYSA-N Cc1cccc(S(NCC(OC(CO)=C2O)=CC2=O)(=O)=O)c1 Chemical compound Cc1cccc(S(NCC(OC(CO)=C2O)=CC2=O)(=O)=O)c1 VXQJFEQLHMJJLG-UHFFFAOYSA-N 0.000 description 1
- CNWWNLNRJOUVKM-UHFFFAOYSA-N NCC(OC=C1OCc2ccccc2)=CC1=O Chemical compound NCC(OC=C1OCc2ccccc2)=CC1=O CNWWNLNRJOUVKM-UHFFFAOYSA-N 0.000 description 1
- YOLAJLQYUHVDAA-UHFFFAOYSA-N O=C1C(/[O]=C/c2ccccc2)=COC(CNS(C(C2)C=CC=C2Cl)(=O)=O)=C1 Chemical compound O=C1C(/[O]=C/c2ccccc2)=COC(CNS(C(C2)C=CC=C2Cl)(=O)=O)=C1 YOLAJLQYUHVDAA-UHFFFAOYSA-N 0.000 description 1
- ZHUHSKMFMJGZLG-UHFFFAOYSA-N OC1=COC(CNS(c(cc2)ccc2Cl)(=O)=O)=CC1=O Chemical compound OC1=COC(CNS(c(cc2)ccc2Cl)(=O)=O)=CC1=O ZHUHSKMFMJGZLG-UHFFFAOYSA-N 0.000 description 1
- RUMWHTIJHAUQTP-CIAFOILYSA-N OCC(OC(/C=N/S(c1ccccc1)(=O)=O)=CC1=O)=C1OCc1ccccc1 Chemical compound OCC(OC(/C=N/S(c1ccccc1)(=O)=O)=CC1=O)=C1OCc1ccccc1 RUMWHTIJHAUQTP-CIAFOILYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750023P | 2013-01-08 | 2013-01-08 | |
| US61/750,023 | 2013-01-08 | ||
| PCT/EP2014/050166 WO2014108407A1 (en) | 2013-01-08 | 2014-01-07 | Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016508145A true JP2016508145A (ja) | 2016-03-17 |
| JP2016508145A5 JP2016508145A5 (OSRAM) | 2017-02-16 |
Family
ID=50070508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551200A Pending JP2016508145A (ja) | 2013-01-08 | 2014-01-07 | ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8952039B2 (OSRAM) |
| EP (1) | EP2943469A1 (OSRAM) |
| JP (1) | JP2016508145A (OSRAM) |
| KR (1) | KR20150103034A (OSRAM) |
| CN (1) | CN104903294A (OSRAM) |
| BR (1) | BR112015016184A2 (OSRAM) |
| CA (1) | CA2894452A1 (OSRAM) |
| HK (2) | HK1212688A1 (OSRAM) |
| MX (1) | MX2015008288A (OSRAM) |
| RU (1) | RU2015125570A (OSRAM) |
| WO (1) | WO2014108407A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016256125B9 (en) | 2015-04-28 | 2020-02-20 | Shionogi And Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
| PL3290424T3 (pl) | 2015-04-28 | 2023-05-08 | Shionogi & Co., Ltd | Podstawione policykliczne pochodne pirydonu i ich prolek |
| CR20180356A (es) | 2015-12-15 | 2018-08-22 | Shionogi & Co | Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza |
| WO2017106820A1 (en) | 2015-12-17 | 2017-06-22 | Thomas Jefferson University | Antiviral agents for drug-resistant influenza a |
| US10889556B2 (en) * | 2016-03-08 | 2021-01-12 | The Regents Of The University Of California | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease |
| KR20190007517A (ko) | 2016-08-10 | 2019-01-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006030807A1 (ja) * | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| JP2007519735A (ja) * | 2004-01-30 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用であるｎ−ベンジル−３，４−ジヒドロキシピリジン−２−カルボキサミド及びｎ−ベンジル−２，３−ジヒドロキシピリジン−４−カルボキサミド化合物 |
| WO2010110231A1 (ja) * | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
-
2014
- 2014-01-07 EP EP14703276.7A patent/EP2943469A1/en not_active Withdrawn
- 2014-01-07 MX MX2015008288A patent/MX2015008288A/es unknown
- 2014-01-07 CN CN201480004181.3A patent/CN104903294A/zh active Pending
- 2014-01-07 JP JP2015551200A patent/JP2016508145A/ja active Pending
- 2014-01-07 BR BR112015016184A patent/BR112015016184A2/pt not_active IP Right Cessation
- 2014-01-07 WO PCT/EP2014/050166 patent/WO2014108407A1/en not_active Ceased
- 2014-01-07 RU RU2015125570A patent/RU2015125570A/ru not_active Application Discontinuation
- 2014-01-07 HK HK16100551.3A patent/HK1212688A1/zh unknown
- 2014-01-07 CA CA2894452A patent/CA2894452A1/en not_active Abandoned
- 2014-01-07 HK HK15112096.1A patent/HK1211287A1/xx unknown
- 2014-01-07 US US14/149,218 patent/US8952039B2/en not_active Expired - Fee Related
- 2014-01-07 KR KR1020157017812A patent/KR20150103034A/ko not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007519735A (ja) * | 2004-01-30 | 2007-07-19 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用であるｎ−ベンジル−３，４−ジヒドロキシピリジン−２−カルボキサミド及びｎ−ベンジル−２，３−ジヒドロキシピリジン−４−カルボキサミド化合物 |
| WO2006030807A1 (ja) * | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| WO2010110231A1 (ja) * | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1212688A1 (zh) | 2016-06-17 |
| US20140194476A1 (en) | 2014-07-10 |
| BR112015016184A2 (pt) | 2017-07-11 |
| EP2943469A1 (en) | 2015-11-18 |
| RU2015125570A (ru) | 2017-02-10 |
| WO2014108407A1 (en) | 2014-07-17 |
| MX2015008288A (es) | 2016-06-02 |
| KR20150103034A (ko) | 2015-09-09 |
| CA2894452A1 (en) | 2014-07-17 |
| CN104903294A (zh) | 2015-09-09 |
| HK1211287A1 (en) | 2016-05-20 |
| US8952039B2 (en) | 2015-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524457A (ja) | ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用 | |
| JP2016508145A (ja) | ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 | |
| JP6033873B2 (ja) | ピリミジン−４−オン誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| JP6047168B2 (ja) | ヘテロアリールヒドロキサム酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| JP2015521189A (ja) | ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体 | |
| JP2016518305A (ja) | ピリミドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 | |
| JP2015517555A (ja) | ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| JP2017521424A (ja) | ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用 | |
| US9505758B2 (en) | Substituted 1,5-naphthyridines as endonuclease inhibitors | |
| US20170081331A1 (en) | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease | |
| CN107001355A (zh) | 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途 | |
| WO2017046350A1 (en) | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150707 |
|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20150904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170106 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171212 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180703 |